BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 15893681)

  • 1. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
    Webb UH
    J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B; Cepok S; Nessler S; Sommer N
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic management of multiple sclerosis.
    Blasier MG
    Urol Nurs; 2008 Jun; 28(3):217-9. PubMed ID: 18605517
    [No Abstract]   [Full Text] [Related]  

  • 12. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
    Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
    Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression followed by immunomodulation.
    Boggild M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S50-4. PubMed ID: 19200868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of multiple sclerosis relapses with immunomodulating agents.
    Johnson KP
    J Neurol Sci; 2007 May; 256 Suppl 1():S23-8. PubMed ID: 17350652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A practical guide to pediatric multiple sclerosis.
    Huppke P; Gärtner J
    Neuropediatrics; 2010 Aug; 41(4):157-62. PubMed ID: 21086219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA; Giovannoni G
    Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
    Thrower BW
    Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.